HELP HIM SEE BEYOND HIS ADHD SYMPTOMS

Vyvanse is proven to help treat pediatric patients with ADHD1-3

In a 4-week, double-blind, randomized, parallel-group study in children 6-12years (N=290) with ADHD, Vyvanse demonstrated significant reduction in ADHD-RS-IV total score from baseline to endpoint for all doses combined (30, 50, 70 mg/day) vs. placebo (43.9 to 19.5 and 42.4 to 36.6, respectively; P<0.0001).

Hypothetical patient portrayal. Individual results may vary.

ONCE-DAILY DOSING & CUSTOMIZABLE ADMINISTRATION

Only Vyvanse (lisdexamfetamine dimesylate) has 5 administration options, so you can tailor treatment to meet the needs of your pediatric ADHD patients (ages 6-17).¹

SHOW YOUR ELIGIBLE PATIENTS HOW THEY COULD SAVE

You’re dedicated to your patients. We’re dedicated to providing a savings offer to help make Vyvanse prescriptions accessible to them. See details. Restrictions apply.

Keep your patients and their caregivers well informed and on the right treatment path with our resources center.

Hypothetical patient portrayal

YOU CAN FIND EXTENSIVE RESOURCES

When it comes to keeping you well-informed about treatment and symptom management options for your patients, our ADHD resource center is available and ready to help.

Are your patients speaking ADHD?

Hypothetical patient portrayal

ABOUT ADHD IN CHILDREN

While it may not be easy for your patients and their caregivers to talk about ADHD symptoms, we offer tips alongside DSM-5®diagnostic criteria that can help start the conversation and support ADHD patient care.

Hypothetical patient portrayal

KEEP IN TOUCH

Stay up to date with the latest information and resources to help support your Vyvanse patients.

New patients from June 2007* to present for all approved indications.

*Vyvanse (lisdexamfetamine dimesylate) has been approved to treat ADHD in pediatric patients since 2007.1

References
  1. Vyvanse [package insert]. Lexington, MA: Shire US Inc.
  2. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29(3):450-463.
  3. Data on file; LDX006; Shire US Inc.

INDICATION AND IMPORTANT SAFETY INFORMATION